Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
The effectiveness of ritonavir-boosted nirmatrelvir (NMV-r) against Omicron variants.
The design, synthesis, and mechanism of action of Paxlovid.
A study in the Emerging Infectious Diseases journal shows treating 20% of COVID-19 patients with Paxlovid could save up to 0.85 million lives and reduce the economic burden by US $170.17 billion in the US.
Recent study reveals nirmatrelvir treatment during acute COVID-19 does not lower the risk of post-acute COVID-19 symptoms, nor is it associated with symptomatic rebound.
A team of researchers from UC San Francisco has found that Paxlovid (Nirmatrelvir-ritonavir) did not reduce the risk of developing long COVID for vaccinated, non-hospitalized individuals during their first COVID-19 infection.
Review explores the global impact of the hepatitis D virus (HDV) on public health, detailing its transmission, clinical course, diagnosis, and treatment options.
Coronaviruses are a global public health risk, with three highly infectious species, including SARS-CoV-2, emerging in the last 20 years.
Review examines nirmatrelvir and bisphosphonates in treating COVID-19, revealing their impact on SARS-CoV-2-specific adaptive immunity and potential to mitigate severe infections, highlighting the need for balanced long-term immunity management.
The frequency of viral rebound (VR) among acute coronavirus disease 2019 patients.
An observational study of patients being treated for acute COVID-19 in a multicenter health care system observed virologic rebound in about 20 percent of patients treated with nirmatrelvir-ritonavir (N-R) versus about 2 percent of those who did not receive treatment. The findings are published in Annals of Internal Medicine.
A new study by investigators from Mass General Brigham found that one in five individuals taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, to treat severe symptoms of COVID-19, experienced a positive test result and shedding of live and potentially contagious virus following an initial recovery and negative test-;a phenomenon known as virologic rebound.
A panel of international experts representing the World Health Organization's Guideline Development Group has updated its guidance on treatments for patients with covid-19.
Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited.
A new mouse model of infection with the COVID-19-causing SARS-CoV-2 virus during pregnancy tracks closely the disease course doctors have observed in SARS-CoV-2-infected pregnant patients, and suggests that treatment with the antiviral Paxlovid provides protection for both mother and child.
Nirmatrelvir and ritonavir treatment significantly reduces the risk of hospitalization and death from COVID-19 in high-risk individuals, according to a recent JAMA Network Open study. However, the treatment's efficacy varied based on the degree of vulnerability, emphasizing tailored approaches for different risk groups.
Today, the National Institutes of Health launched and is opening enrollment for phase 2 clinical trials that will evaluate at least four potential treatments for long COVID, with additional clinical trials to test at least seven more treatments expected in the coming months.
Research investigates the effectiveness of oral antiviral medications, Molnupiravir and Nirmatrelvir-Ritonavir, in treating patients with type 2 diabetes and mild to moderate COVID-19. The study aims to determine the efficacy of these medications in reducing adverse outcomes in this specific population.
Researchers discuss the use of endo-lysosome-targeted nanoparticles for delivering antiviral therapy to treat coronavirus infections.
Researchers assess whether nirmatrelvir/ritonavir treatment reduced the risk of COVID-19-related hospitalization.
Among high-risk individuals, molnupiravir treatment in the acute phase of infection could prevent long COVID.